Skip to content

Bio-Techne

US · TECH #1365 by market cap Listed 1970
72.53 +0.10 +0.14%
Live - 5344 symbols - heartbeat 51s ago · 2026-10-08 07:40
Pre-market 72.53 0.00%
After-hours 72.53 0.00%
Market cap
11.37B
P/B
5.39
EPS
1.16
Reader sentiment Are you bullish or bearish on TECH?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 4 in the most recent period (2026/Q3).
  • Total institutional ownership fell 0.5 percentage points.

Institutional ownership

Held by institutions
113.54% -0.49pp
Institutions
686 -4
As of
2026/Q3 vs. prior period

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Holder types

Mutual Fund86.05%
Hedge Fund15.62%
Public Company7.43%
Government Pension Fund1.57%
Private Company0.92%
Sovereign Wealth Fund0.90%
Family Office/Trust0.45%
Insurance Company0.39%
Individual/Insider0.35%

Top holders as of 2026-06-30

BlackRock 8.94% · 14.03M sh
FMR 8.14% · 12.76M sh
Vanguard Capital Management, LLC 7.08% · 11.10M sh
HBK Investments L.P. 4.35% · 6.83M sh
Vanguard Portfolio Management, LLC 4.15% · 6.51M sh
The Goldman Sachs Group, Inc. 4.00% · 6.27M sh
State Street Global Advisors 3.81% · 5.98M sh
Geode Capital Management, LLC 3.41% · 5.35M sh
Eaton Vance Management 3.05% · 4.78M sh
Invesco Capital Management LLC 2.89% · 4.54M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 24 buys · 26 sells

NameRoleStake
James Hippel Chief Financial Officer 0.11%
Kim Kelderman President of Diagnostics & Genomics 0.05%
John Higgins Independent Director 0.05%
Robert Baumgartner Independent Chairperson 0.04%
Roeland Nusse Independent Director 0.03%
William Geist President of Protein Sciences Segment 0.02%
Alpna Seth Independent Director 0.01%
Joseph Keegan Independent Director 0.01%
S.J. Vessey Independent Director 0.01%
Shane Bohnen Senior Vice President 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-27 John Higgins Independent Director Derivative Exercise and Sale -5,562 $72.51
2026-09-27 John Higgins Independent Director Derivative Exercise and Retained +10,378 --
2026-09-21 Robert Baumgartner Independent Chairperson Derivative Exercise and Sale -5,559 $72.55
2026-09-21 Robert Baumgartner Independent Chairperson Derivative Exercise and Retained +10,381 --
2026-08-16 Kim Kelderman President of Diagnostics & Genomics Other Derivative Acquisition +151,172 --
2026-08-16 Steven Crouse Senior Vice President of Analytical Solutions Division Other Derivative Acquisition +22,842 --
2026-08-16 James Hippel Chief Financial Officer Other Derivative Acquisition +58,897 --
2026-08-16 Amy Herr Independent Director Other Derivative Acquisition +1,381 --
2026-08-16 William Geist President of Protein Sciences Segment Other Derivative Acquisition +38,747 --
2026-08-16 Shane Bohnen Senior Vice President Other Derivative Acquisition +29,776 --
2026-08-14 Kim Kelderman President of Diagnostics & Genomics Derivative Sale to Issuer -46,713 --
2026-08-14 Kim Kelderman President of Diagnostics & Genomics Derivative Sale to Issuer -17,154 --
2026-08-14 Kim Kelderman President of Diagnostics & Genomics Derivative Exercise and Sale -10,821 $72.40
2026-08-14 Kim Kelderman President of Diagnostics & Genomics Derivative Exercise and Retained +10,649 --
2026-08-14 Steven Crouse Senior Vice President of Analytical Solutions Division Derivative Exercise and Sale -1,947 $72.40
2026-08-14 Steven Crouse Senior Vice President of Analytical Solutions Division Derivative Exercise and Retained +3,476 --
2026-08-14 James Hippel Chief Financial Officer Derivative Sale to Issuer -34,982 --
2026-08-14 James Hippel Chief Financial Officer Derivative Sale to Issuer -12,999 --
2026-08-14 James Hippel Chief Financial Officer Derivative Exercise and Sale -4,310 $72.40
2026-08-14 James Hippel Chief Financial Officer Derivative Exercise and Retained +5,469 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-10-08 07:40:17 · For reference only, not investment advice and not tailored to your situation.